Is Asthma Remission a New Achievable Goal? A Review of the Current Drug-Related Evidence and Predictors
Allergy: European Journal of Allergy and Clinical Immunology, cilt.81, sa.9, ss.3107-3129, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 81 Sayı: 9
- Basım Tarihi: 2026
- Doi Numarası: 10.1111/all.70388
- Dergi Adı: Allergy: European Journal of Allergy and Clinical Immunology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Food Science & Technology Abstracts, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Sayfa Sayıları: ss.3107-3129
- Anahtar Kelimeler: airway remodeling, asthma, biologics, remission, severe asthma
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and super-responders, remission criteria in severe asthma studies with biologics, and future perspectives. The terminology of asthma remission basically describes a high level of disease control, which includes the absence of symptoms and exacerbations, avoiding the use of oral corticosteroids and stability of lung function with/without continuation of treatment. Predictors associated with spontaneous remission include younger age at asthma onset, milder symptoms at diagnosis, male sex, and higher baseline lung function. Biologic therapies have shown considerable success in achieving remission in asthma; however, predictors of response to these therapies remain heterogeneous and are not consistently defined across studies.